TLSA — Tiziana Life Sciences Share News
0.000.00%
Last trade - 00:00- $115.83m
- $113.58m
U.S. STOCKS ON THE MOVE-Core Scientific, gold miners, Cognizant
Brief: Tiziana Life Sciences Ltd. Granted 180-Day Extension By Nasdaq To Meet Minimum Bid Price Requirements
Brief: Tiziana Life Sciences To Focus On Intranasal Foralumab Central Nervous System Diseases
Brief: Tiziana Life Sciences Completes Enrollment Of The First Patient Cohort For Intermediate-Size Patient Population Expanded Access Program
Brief: Tiziana Life Sciences Starts Enrollment Of The First Patient Cohort In Its Intermediate Size Patient Population Expanded Access Program To Evaluate Foralumab In Non-Active Secondary Multiple Sclerosis Patients
U.S. STOCKS ON THE MOVE-Novavax, Tiziana, Hempacco
Tiziana to seek FDA's nod to begin Alzheimer's drug trial; shares up
Brief: Tiziana Life Sciences Plans To Submit Ind For Phase 1 Trial Of Intranasal Foralumab In Alzheimer's Disease Patients
Brief: Tiziana Life Sciences Announces Purchase Of Common Shares By Executive Chairman
Brief: Tiziana Life Sciences Announces Grant Received By The Brigham And Women’S Hospital To Explore The Use Of Intranasal Anti-Cd3 Mab In Amyotrophic Lateral Sclerosis
Brief: Tiziana Life Sciences Announces Purchase Of Common Shares By Chief Medical Officer
Brief: Tiziana Life Sciences Announces Purchase Of Common Shares By Executive Chairman
Brief: Tiziana Life Sciences Announces Purchase Of Common Shares By Executive Chairman
Brief: Tiziana Life Sciences Reports Resignation Of CEO
Brief: Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice
Brief: Tiziana Life Sciences Announces Purchase Of Common Shares By Executive Chairman
Brief: Tiziana Life Sciences Announces Purchase Of Common Shares By Executive Chairman
Brief: Tiziana Life Sciences Announces Results From Second Patient With Secondary Progressive Multiple Sclerosis Following Three Months Of Dosing With Intranasal Foralumab
Brief: Tiziana Life Sciences Files Annual Report To Regain Nasdaq Compliance